Philadelphia Trust Company’s VanEck Biotech ETF BBH Stock Holding History

Philadelphia Trust Company’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$224K	Hold	1,100	–	–	0.01%	250
2026 Q1	$207K	Hold	1,100	–	–	0.01%	251
2025 Q4	$208K	Buy	+1,100	New	+$204K	0.01%	239

Other funds holding BBH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Philadelphia Trust Company's BBH Position: Q2 2026 in Review

Philadelphia Trust Company held its VanEck Biotech ETF (BBH) position steady in Q2 2026 at 1,100 shares worth $224K. The position accounts for 0.01% of the portfolio, ranked #250.

Philadelphia Trust Company first reported a position in BBH in Q4 2025 and has held it in 3 quarters since. 110 funds tracked by Wall St. Rank hold BBH as of Q2 2026.

Philadelphia Trust Company held 1,100 shares of VanEck Biotech ETF worth $224K as of Q2 2026.
Philadelphia Trust Company left its VanEck Biotech ETF share count unchanged in Q2 2026.
VanEck Biotech ETF made up 0.01% of Philadelphia Trust Company's portfolio in Q2 2026, its #250 holding.
Philadelphia Trust Company first reported a position in VanEck Biotech ETF in Q4 2025 and has held it in 3 quarters since.
110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.

Based on Philadelphia Trust Company's 13F filing for Q2 2026, filed 10 Aug 2026.